Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit
Hydration is needed before and after cisplatin infusion for reducing the risk of nephrotoxicity. Even though there is no standard regimen, patients receive mostly intravenous hydration before and after cisplatin leading hospitalization during at least one night. Since the feasibility has been published, oral hydration after cisplatin was implemented in our practice. The safety of this new way of hydration needs to be assessed in clinical practice.
We collected medical records from patients treated by cisplatin for lung cancer in our unit between 2010 and 2016. We retrospectively analyzed the incidence of cisplatin induced nephrotoxicity between after and before the change of hydration regimen.
Our patient cohort included 241 patients hydrated by intravenous regimen (IV/IV group) and 276 patient hydrated by intravenous and oral regimen (IV/PO group). Grade ≥ 1 nephrotoxicity occurred in 39.4 and 25.7% in the IV/IV and IV/PO groups respectively (p = 0.001). Age over 70 at baseline was a predictive factor for nephrotoxicity, but not estimated glomerular filtration rate nor cisplatin-associated drugs. After a multivariate analysis, age remained a predictive factor for nephrotoxicity and IV/PO hydration associated with a decrease in nephrotoxic risk.
The implementation of oral hydration in our practice was not associated with an increase in nephrotoxicity. Our observation based on large data from clinical practice shows that oral hydration after cisplatin is safe.
KeywordsLung cancer Cisplatin Nephrotoxicity Oral hydration Outpatient
Compliance with ethical standards
This study was performed in the respect for ethical consideration of research involving human participant. Since it was a retrospective study based on existing data, formal consent is not required.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH, American Society of Clinical Oncology Clinical Practice (2015) Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(30):3488–3515. https://doi.org/10.1200/JCO.2015.62.1342 CrossRefGoogle Scholar
- 7.Launay-Vacher V, Rey J-B, Isnard-Bagnis C, Deray G, Daouphars M (2008) European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61(6):903–909. https://doi.org/10.1007/s00280-008-0711-0 CrossRefGoogle Scholar
- 8.Fukushima K, Okada A, Oe H, Hirasaki M, Hamori M, Nishimura A, Shibata N, Sugioka N (2018 Apr) Pharmacokinetic-pharmacodynamic analysis of cisplatin with hydration and mannitol diuresis: the contribution of urine cisplatin concentration to nephrotoxicity. Eur J Drug Metab Pharmacokinet 43(2):193–203. https://doi.org/10.1007/s13318-017-0436-8 CrossRefGoogle Scholar
- 10.Lavolé A, Danel S, Baudrin L et al (2012) Routine administration of a single dose of cisplatin ≥75mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer (Paris) (4):43–48. https://doi.org/10.1684/bdc.2012.1555
- 12.Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute dialysis quality initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care Lond Engl 8(4):R204–R212. https://doi.org/10.1186/cc2872 CrossRefGoogle Scholar
- 14.Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcisło K, Szczylik C (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer Oxf Engl 1990 44(17):2608–2614. https://doi.org/10.1016/j.ejca.2008.08.005 Google Scholar
- 16.Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5(2):304–309. https://doi.org/10.1200/JCO.19220.127.116.114 CrossRefGoogle Scholar
- 17.Sassier M, Dugué AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, le Caer H, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R (2015) Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. Lung Cancer 89(2):161–166. https://doi.org/10.1016/j.lungcan.2015.05.005 CrossRefGoogle Scholar
- 19.Sato K, Watanabe S, Ohtsubo A et al (2016) Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 16(1). https://doi.org/10.1186/s12885-016-2271-8
- 20.Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, di Salvia R, de Marinis F, Ardizzoni A (2007) Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 93(2):138–144CrossRefGoogle Scholar
- 22.Yamaguchi T, Uozu S, Isogai S, Hayashi M, Goto Y, Nakanishi T, Imaizumi K (2017) Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis. Support Care Cancer 25(4):1215–1220. https://doi.org/10.1007/s00520-016-3512-8 CrossRefGoogle Scholar
- 23.Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung Cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 43(11):1115–1123. https://doi.org/10.1093/jjco/hyt128 CrossRefGoogle Scholar
- 24.Ninomiya K, Hotta K, Hisamoto-Sato A, Ichihara E, Gotoda H, Morichika D, Tamura T, Kayatani H, Minami D, Kubo T, Tabata M, Tanimoto M, Kiura K (2016) Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol 21(1):81–87. https://doi.org/10.1007/s10147-015-0860-1 CrossRefGoogle Scholar
- 25.Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T (2013) Short hydration in chemotherapy containing cisplatin (>=75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 43(11):1105–1109. https://doi.org/10.1093/jjco/hyt122 CrossRefGoogle Scholar
- 26.Sato J, Morikawa N, Nitanai H et al (2016) Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer. J Pharm Health Care Sci 2(1). https://doi.org/10.1186/s40780-016-0041-z